Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Passaro

Showing results (91-100 of 1,100) with videos related to

Pageof 110
Sort By:
Sensors (Basel, Switzerland)|June 28, 2012
Optimizing SOI slot waveguide fabrication tolerances and strip-slot coupling for very efficient optical sensingVittorio M N Passaro, Mario La Notte
The Journal of Vascular Access|August 25, 2020
The fibroblastic sleeve, the neglected complication of venous access devices: A narrative reviewGiovanna Passaro, Mauro Pittiruti, Antonio La Greca
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2023
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing StrategiesAntonio Passaro, Pasi A Jänne, Solange Peters
Pulmonology|December 18, 2018
Immunotherapy in refractory SCLC: the caterpillar struggling to become a butterflyAntonio Passaro, Valeria Stati, Filippo de Marinis
Expert Review of Anticancer Therapy|October 18, 2011
Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Antonio Passaro, Enrico Cortesi, Filippo de Marinis
Clinical Lung Cancer|March 21, 2020
ReplyAntonio Passaro, Gianluca Spitaleri, Filippo de Marinis
Journal of Thoracic Disease|August 31, 2013
Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trialsAntonio Passaro, Bruno Gori, Filippo de Marinis
Lung Cancer (Amsterdam, Netherlands)|October 2, 2013
Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancerFilippo de Marinis, Antonio Passaro, Stephen Clarke
Expert Review of Anticancer Therapy|July 9, 2016
First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?Antonio Passaro, Gianluca Spitaleri, Filippo de Marinis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2022
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung CancerAntonio Passaro, Ilaria Attili, Filippo de Marinis
Pageof 110

Showing results (91-100 of 1,100) with videos related to

Sort By:
Pageof 110
Sensors (Basel, Switzerland)|June 28, 2012
Optimizing SOI slot waveguide fabrication tolerances and strip-slot coupling for very efficient optical sensingVittorio M N Passaro, Mario La Notte
The Journal of Vascular Access|August 25, 2020
The fibroblastic sleeve, the neglected complication of venous access devices: A narrative reviewGiovanna Passaro, Mauro Pittiruti, Antonio La Greca
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2023
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing StrategiesAntonio Passaro, Pasi A Jänne, Solange Peters
Pulmonology|December 18, 2018
Immunotherapy in refractory SCLC: the caterpillar struggling to become a butterflyAntonio Passaro, Valeria Stati, Filippo de Marinis
Expert Review of Anticancer Therapy|October 18, 2011
Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Antonio Passaro, Enrico Cortesi, Filippo de Marinis
Clinical Lung Cancer|March 21, 2020
ReplyAntonio Passaro, Gianluca Spitaleri, Filippo de Marinis
Journal of Thoracic Disease|August 31, 2013
Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trialsAntonio Passaro, Bruno Gori, Filippo de Marinis
Lung Cancer (Amsterdam, Netherlands)|October 2, 2013
Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancerFilippo de Marinis, Antonio Passaro, Stephen Clarke
Expert Review of Anticancer Therapy|July 9, 2016
First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?Antonio Passaro, Gianluca Spitaleri, Filippo de Marinis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2022
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung CancerAntonio Passaro, Ilaria Attili, Filippo de Marinis
Pageof 110